PHATHOM PHARMACEUTICALS, INC. Cost of Revenue
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Cost of Revenue of $15.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2026-06-30 was $15.10M, a 199.64% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2026-03-31 was $12.00M, a 222.13% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2025-12-31 was $7.65M, a 100.47% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2025-09-30 was $6.19M, a 162.73% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for fiscal 2025 was $22.60M, a 183.44% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for fiscal 2024 was $7.97M, a 4674.25% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for fiscal 2023 was $167.00K.
- PHATHOM PHARMACEUTICALS, INC. cost of revenue for fiscal 2022 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.10M 10-Q · filed 2026-07-30 | $27.09M 10-Q · filed 2026-07-30 | $34.74M derived: sum of 3 quarters · filed 2026-07-30 | $40.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $12.00M 10-Q · filed 2026-04-30 | $19.64M derived: sum of 2 quarters · filed 2026-04-30 | $25.83M derived: sum of 3 quarters · filed 2026-04-30 | $30.87M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.84M derived: sum of 2 quarters · filed 2026-02-26 | $18.88M derived: sum of 3 quarters · filed 2026-07-30 | $22.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.19M 10-Q · filed 2025-10-30 | $11.23M derived: sum of 2 quarters · filed 2026-07-30 | $14.95M 10-Q · filed 2025-10-30 | $18.77M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $5.04M 10-Q · filed 2026-07-30 | $8.76M 10-Q · filed 2026-07-30 | $12.58M derived: sum of 3 quarters · filed 2026-07-30 | $14.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.72M 10-Q · filed 2026-04-30 | $7.54M derived: sum of 2 quarters · filed 2026-04-30 | $9.89M derived: sum of 3 quarters · filed 2026-04-30 | $11.27M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.17M derived: sum of 2 quarters · filed 2026-02-26 | $7.55M derived: sum of 3 quarters · filed 2026-02-26 | $7.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.36M 10-Q · filed 2025-10-30 | $3.73M derived: sum of 2 quarters · filed 2025-10-30 | $4.16M 10-Q · filed 2025-10-30 | $4.33M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $1.38M 10-Q · filed 2025-08-07 | $1.80M 10-Q · filed 2025-08-07 | $1.97M derived: sum of 3 quarters · filed 2025-08-07 | $1.97M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $426.00K 10-Q · filed 2025-05-01 | $593.00K derived: sum of 2 quarters · filed 2025-05-01 | $593.00K derived: sum of 3 quarters · filed 2025-05-01 | $593.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $167.00K derived: sum of 2 quarters · filed 2025-03-06 | $167.00K derived: sum of 3 quarters · filed 2025-03-06 | $167.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |